Linnaeus announced today announced that it has entered into a clinical collaboration agreement with Merck to evaluate the combination of its lead investigational product candidate LNS8801, and Merck’s anti-PD-1 therapy, KEYTRUDA®(pembrolizumab) in patients with selected advanced solid tumors. Haddonfield NJ, June 23, 2020--Linnaeus Therapeutics, Inc. (Linnaeus), a privately [...]

Linnaeus Therapeutics Scientific Cofounders Publish Preclinical Pancreatic Cancer Data in Cellular and Molecular Gastroenterology and Hepatology Haddonfield NJ, June 10, 2020 -- Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule oncology therapeutics, today announced that its [...]

Linnaeus Therapeutics Announces FDA Clearance of Investigational New Drug Application for LNS8801 Haddonfield NJ, September 24, 2019--Linnaeus Therapeutics, Inc. (Linnaeus), a privately held, clinical-stage biopharmaceutical company focused on the development and commercialization of novel, small molecule oncology therapeutics, today announced that the U.S. Food and Drug [...]

Linnaeus Therapeutics Scientific Cofounder Presents Preclinical Pancreatic Cancer Data at AACR Pancreas Cancer Meeting Linnaeus Therapeutics, Inc. (“Linnaeus”), a privately held biopharmaceutical company focused on the development and commercialization of novel, small molecule oncology therapeutics, today announced that its scientific cofounder, Todd Ridky, MD, PhD, Assistant Professor [...]

Linnaeus Therapeutics Appoints Tina Garyantes, Ph.D., to Senior Vice President of Research and Development Haddonfield NJ, September 1, 2018--Linnaeus Therapeutics, Inc. (“Linnaeus”), a privately held biopharmaceutical company focused on the development and commercialization of novel, small molecule oncology therapeutics, today announced the appointment of Tina Garyantes, Ph.D., [...]